Drug Trial Radar · NCT07435428
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,305
Actual
Start
Feb 18, 2026
Primary completion
Sep 28, 2026
Study completion Sep 11, 2028
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effectiveness and safety of a single dose of Corabotase (also known as IPN10200) compared to placebo (double-blind phase) and how well and safely repeat doses of Corabotase work over time (open-label phase) in adult participants with moderate to severe glabellar lines. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence. All participants in the double-blind phase will receive Corabotase or placebo during the first treatment cycle. De novo participants in the open-label phase will receive IPN10200 during the first treatment cycle. Some participants may receive additional treatment cycles with Corabotase depending on their eligibility. There will be 3 periods in this study: * A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period where participants may receive up to 4 treatment cycles. In the double-blind phase, participants receive a single treatment of Corabotase or placebo. In the open-label phase (rollover participants from double-blind), eligible participants may receive additional cycles of Corabotase . In the open-label phase (de novo participants), participants will receive Corabotase in the first cycle and eligible participants may receive additional cycles of Corabotase. Requires multiple visits during the first month followed by 1 visit every month. * A follow-up period (24 weeks) after the last injection where participants' health will be monitored. Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 107 weeks. Participants may withdraw consent to participate at any time.
Conditions
- Moderate to Severe Glabellar Lines
Interventions
CorabotaseBiological
A single vial of lyophilised powder for solution for injection will be injected locally into several sites across the glabellar region.
PlaceboBiological
A single vial of lyophilised powder for solution, containing excipients without active substance, will be injected locally into several sites across the glabellar region.
Primary outcomes
What the sponsor says the trial is designed to measure.
- For North America: Percentage of participants responding to treatmentTime frame: At week 4
- For EU and ROW: Percentage of participants responding to treatment as measured by ≥2-grades improvement on the ILA at maximum frownTime frame: From baseline to week 4
Locations
60 sites in 4 countries. Site status is shown where the registry gives one.
Rivkin Westside Aesthetics
Los Angeles, California
Clinical Testing of Beverly Hills
Los Angeles, California
Eye Research Foundation
Newport Beach, California
Steve Yoelin MD Medical Associates Inc
Newport Beach, California
Skin and Beauty Center
Pasadena, California
Dermatology Cosmetic Laser Medical Associates of La Jolla Inc.
San Diego, California
Southern California Dermatology, Inc.
Santa Ana, California
DMR Research, PLLC
Westport, Connecticut
Center for Dermatology and Dermatologic Surgery
Washington D.C., District of Columbia
Skin and Cancer Associates (SCA) and the Center for Cosmetic Enhancement (CCE) - Aventura
Aventura, Florida
Weinkle Dermatology
Bradenton, Florida
Skin Research Institute
Coral Gables, Florida
Miami Dermatology & Laser Research
Miami, Florida
Kavali Plastic Surgery and Skin Renewal Center
Atlanta, Georgia
DeNova Research
Chicago, Illinois
Chicago Cosmetic and Dermatologic Research
Chicago, Illinois
Advanced Dermatology, A Forefront Dermatology Practice
Lincolnshire, Illinois
LASSI - Laser and Skin Surgery Center of Indiana
Indianapolis, Indiana
Coleman Center For Cosmetic Dermatologic Surgery
Metairie, Louisiana
DelRicht Research
New Orleans, Louisiana
Etre, Cosmetic Dermatology and Laser Center
New Orleans, Louisiana
Maryland Laser, Skin, & Vein Institute, LLC (MDLSV)
Hunt Valley, Maryland
Lawrence J. Green, MD. LLC
Rockville, Maryland
SkinCare Physicians
Chestnut Hill, Massachusetts
Michigan Center for Research Company
Clarkston, Michigan
Skin Specialists PC dba Schlessinger MD
Omaha, Nebraska
StracSkin
Portsmouth, New Hampshire
Rejuva Center at Williams
Latham, New York
The Center for Dermatology, Cosmetic & Laser Surgery
Mount Kisco, New York
Luxurgery
New York, New York
Dr. Z. Paul Lorenc MD, Office Of
New York, New York
Skin Search Of Rochester, Inc.
Rochester, New York
Rochester Dermatologic Surgery, P.C.
Victor, New York
Aesthetic Solutions P.A.
Chapel Hill, North Carolina
Dermatology, Laser & Vein Specialists of the Carolinas (DLVSC) - Charlotte Office
Charlotte, North Carolina
Nash Research Group, LLC
Powell, Ohio
Oregon Dermatology and Research Center
Portland, Oregon
Paddington Testing Company
Philadelphia, Pennsylvania
Brian S. Biesman MD, PLLC
Nashville, Tennessee
Tennessee Clinical Research Center
Nashville, Tennessee
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.